We searched for JAK2 exon 12 mutations in patients with JAK2 (V617F)-negative myeloproliferative disorders. Seventeen patients with polycythemia vera (PV), including 15 sporadic cases and 2 familial cases, carried deletions or duplications of exon 12 in circulating granulocytes but not in T-lymphocytes. Two of the 8 mutations detected were novel, and the most frequent ones were N542-E543del and E543-D544del. Most patients with PV carrying an exon 12 mutation had isolated erythrocytosis at clinical onset, unlike patients with JAK2 (V617F)-positive PV, most of whom had also elevations in white blood cell and/or platelet counts. Both patients with familial PV carrying an exon 12 mutation had an affected sibling with JAK2 (V617F)-positive PV. Thus, several somatic mutations of JAK2 exon 12 can be found in a myeloproliferative disorder that is mainly characterized by erythrocytosis.
Introduction
The identification of a unique gain-of-function mutation of the Janus kinase 2 (JAK2) gene in patients with chronic myeloproliferative disorders [1] [2] [3] [4] [5] has provided clinicians with a very useful diagnostic tool. In fact, the JAK2 (V617F) mutation can be detected in about 95% of patients with polycythemia vera (PV), and in over half of those with essential thrombocythemia (ET) or primary myelofibrosis (PMF). 1, [6] [7] [8] While only a minority of sporadic patients with PV do not carry JAK2 (V617F), the proportion of familial cases of PV that are negative is definitely higher. 9, 10 Moreover, most patients with idiopathic erythrocytosis do not carry JAK2 (V617F) in circulating granulocytes.
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The JAK2 (V617F) mutation involves the exon 14, which encodes a part of the JH2
auto-inhibitory domain of the JAK2 kinase. Scott and coworkers 12 recently described mutations of JAK2 exon 12 in JAK2 (V617F)-negative patients with PV or idiopathic erythrocytosis. Their findings have been later confirmed by other studies. [13] [14] [15] [16] [17] Using cellular models, it has been shown that exon 12 mutations can activate pathways associated with erythropoietin signaling, and in a murine model one of these mutations resulted in a myeloproliferative phenotype. 12 In this work, we searched for exon 12 mutations in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Materials and Methods
We studied 147 patients with JAK2 (V617F)-negative myeloproliferative disorders.
These investigations were approved by the local ethics committees of Pavia, Basel 19 Of the 147 patients reported in this work, 26 had sporadic PV, 11
had familial PV, 9,10 75 had sporadic ET, and 35 had sporadic PMF.
The isolation of granulocytes and T lymphocytes was performed as previously described. 6, 20 Quantitative real-time polymerase chain reaction (qRT-PCR)-based allelic discrimination assays 6, 7 were used for the detection of the JAK2 (V617F) mutation.
For exon 12 mutations screening, primers were designed to amplify a region of 453 bp containing the 128 bp of the exon 12 as described in Supplemental Methods.
Direct sequencing was performed using the Big Dye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA) and an ABI Prism 3130
Genetic Analyzer (Applied Biosystems).
Results and Discussion
Of the 147 patients with JAK2 (V617F)-negative myeloproliferative disorders, 17
carried mutations of exon 12 in circulating granulocytes. Specifically, exon 12 mutations were detected in 15/26 sporadic cases and in 2/11 familial cases of PV. All positive patients met the revised WHO criteria 21 for PV. Demographic and hematologic characteristics of these patients, and details of their mutations are reported in Table 1 . A comparison between patients with sporadic PV who carried a JAK2 exon 12 mutation and those who did not is reported in Table S1 . Overall, 8 different mutations were found in this study, and the two duplications are novel at the time of this writing. All mutations were detected in circulating granulocytes but not in T-lymphocytes, indicating that these were acquired somatic mutations. The pattern on sequencing was heterozygous in 16 out of 17 patients (Table 1) The present study confirms previous observations on JAK2 exon 12 mutations in myeloproliferative disorders, describes two novel mutations, and provides evidence for intra-family discordance of JAK2 mutation type in familial disorders.
The seminal study by Scott and coworkers 12 led to the conclusion that JAK2 exon 12 mutations define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of PV or idiopathic erythrocytosis. Our findings confirm that these patients indeed have a myeloproliferative syndrome presenting mainly with isolated erythrocytosis associated with suppressed erythropoietin production. Exon 12 mutations were shown to be associated with peculiar biochemical abnormalities of JAK2 signaling, 12 which likely favor erythrocytosis.
Of our 17 patients carrying exon 12 mutations, all but one had heterozygous patterns on sequencing (Table 1 and Figure S1 ). In our original report on the unique JAK2 (V617F) mutation, 4 48/83 (58%) JAK2 (V617F)-positive patients with PV showed a heterozygous pattern on sequencing, while the remaining 35/83 (42%) had a homozygous pattern. These observations may suggest that mitotic recombination,
i.e., the mechanism leading to homozygosity, 4 is more likely to occur in PV patients carrying JAK2 (V617F) than in those with exon 12 mutations.
Variable proportions of patients with JAK2 (V617F)-negative PV that carry an exon 12 mutation have been reported. 12, 13, [15] [16] [17] We used direct sequencing, which allowed us to identify novel mutations but is unlikely to detect percentages of mutant alleles lower than 10%. At least a portion of our negative PV patients (Table S1 ) might therefore carry low percentages of mutant alleles in granulocytes. The inability of direct sequencing to detect them may justify the discrepancy between our findings and those of previous reports.
12,13
Studies of families with myeloproliferative disorders 9, 10, 23, 24 showed that JAK2 (V617F) represents an acquired somatic mutation in familial cases as it does in sporadic cases, 25 and that a genetic predisposition to acquisition of JAK2 (V617F) is inherited. The current study indicates that this predisposition regards any type of JAK2 mutations, not just JAK2 (V617F). It might be hypothesized that these individuals have defective mechanisms for repairing or neutralizing spontaneous mutations, so that those involving gain-of-function emerge and lead to clonal proliferation. In addition, if one considers the two families reported in Figure 2 , only few individuals in these families have a disease phenotype. This makes the distinction between familial and sporadic cases more subtle, and raises the question as whether a genetic predisposition is present also in the so-called sporadic cases. Each family member is identified by a pedigree number. Circles represent female family members; squares male family members; filled symbols members with phenotypically expressed myeloproliferative disorder; slashes members who had died.
In family no. 1, two brothers (II-1 and II-5) had PV. Subject II-1 presented at the age of 57 with ischemic stroke, and at the age of 63 he was diagnosed with PV (erythrocytosis and thrombocytosis). This patient was later found to be JAK2 (V617F)-positive, and his granulocyte mutant alleles increased from 6% to 20% over time. He died at the age 69 of pulmonary embolism despite low dose aspirin and cytoreductive treatment. His brother (subject II-5) was found to have erythrocytosis on routine blood counts at the age of 58; a diagnosis of PV was made, and venesection therapy was started. He was found to carry the N542-E543del mutation in circulating granulocytes.
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